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Abstract. Objective and Design:This study examines the
local and regional effects of exogenously administered inter-
leukins 10 (IL-10) and 12 (IL-12) on pulmonary granulomas
mediated by Th1/type 1-(IFN-g) and Th2/type 2-(IL-4, IL-5)
cytokines.
Materials and Treatments:Granulomas (GR) were induced
in presensitized CBA mice by embolization of beads coated
with Mycobacteria tuberculosisor Schistosoma mansoniegg
antigens. Before challenge, osmotic pumps distributing
IL-10 or IL-12 (50mg/kg/day) were implanted intraperito-
neally, then GR and draining lymph nodes were examined
4 days.
Methods:GR sizes and composition were determined by
morphometry and differential analysis. Isolated GR macro-
phages and draining lymph nodes were assessed for cytokine
production by ELISA.
Results: IL-10 did not effect GR sizes but reduced
neutrophils in type 1 GR. IL-12 minimally reduced type 1
GR but decreased the type 2 lesion by up to 70%, primarily
curtailing eosinophils. Type 2 GR macrophages were
unaffected but type 1 were impaired by IL-10. Conversely,
type 1 GR macrophages were more resistant to IL-12 while
type 2 showed enhanced IL-10, IL-12 and TNF, but reduced
MCP-1 production. In lymph nodes, IL-10 caused paradoxi-
cal effects, enhancing IFN-g in the type 1 and decreasing
Th2 cytokines in the type 2 response. Exogenous IL-12
profoundly augmented IFN-g and abrogated type 2 cytokines
while inhibiting intrinsic IL-12 production in lymph nodes.
Conclusion: These findings provide novel information
regarding cytokine regulation and the effects of systemic
cytokine therapy.
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Introduction
Interleukins 10 (IL-10) and 12 (IL-12) are thought to be
critical cytokines regulating the nature and extent of T helper
(Th) cell functions and inflammatory events [1, 2]. IL-10,
produced by macrophages and Th2 cells, is known to inhibit
the production of a number of proinflammatory cytokines
such as interferon-g (IFN-g) interleukin-1 (IL-1) and tumor
necrosis factor (TNF) [3–5]. IL-12, produced by macro-
phages and lymphocytes, promotes IFN-g production and is
known to augment natural killer and Th1 cell-mediated
immune reactions [6, 7]. It is not surprising that these
cytokines are considered potential therapeutic agents for
manipulation of immune and inflammatory responses. For
example, recombinant IL-10 combined with IL-4 can inhibit
cell-mediated inflammation [8]. In contrast, recombinant
IL-12 enhanced Th1 cell-mediated resistance to intracellular
parasites such asLeishmania[9, 10] and inhibits Th2 cell-
mediated responses to schistosome eggs [11, 12].
To date, studies using cytokines as immunopharmaco-
logic agents generally use a variety of nonstandardized disease
models with variable object parameters. Understanding the
potentially complex in vivo effects of these treatments would
be enhanced by using standardized approaches. We recently
described standardized murine models of type 1 (Th1) and
type 2 (Th2)-cytokine-mediated pulmonary granulomatous
(GR) inflammation elicited with polymer beads coated with
purified protein derivative ofMycobacteria tuberculosis
(PPD) or solubleSchistosoma mansoniegg antigens (SEA)
[13, 14]. Using these models, we report the effect of slow
release recombinant IL-10 and IL-12 on parameters of
leukocyte infiltration, inflammatory macrophage function,
and lymphocyte maturation in draining lymph nodes. Our
results show that the cytokine treatments have both common
and divergent effects in the two models. The data also
emphasize the importance of understanding the spectrum of
counter-regulatory mechanisms invoked by exogenous
cytokine treatment.
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Materials and methods
Animals
Female, CBA/J (The Jackson Laboratories, Bar Harbor, ME, USA)
mice were used in all experiments. Mice were maintained under specific
pathogen-free conditions and provided with food and water ad libitum.
Sensitization and granuloma induction
Pulmonary granulomas with predominantly type 1 or type 2 cytokine
involvement were generated as previously described [13]. Briefly, mice
were sensitized by i.p. injection of 4 mg (wet weight) of live Bacille-
Calmette-Guerin (BCG) strain ofM. bovis (Organon Technika,
Durham, NC, USA) or 3000S. mansonieggs suspended in 0.5 ml
phosphate buffered saline (PBS). Fourteen to 16 days later BCG and
egg sensitized mice were respectively challenged by i.v. with 6000
Sepharose 4B beads (in 0.5 ml PBS) covalently coupled with purified
protein derivative (PPD) ofM. tuberculosisor soluble schistosome egg
antigens (SEA) obtained from the World Health Organization, Geneva,
Switzerland.
Cytokines
Recombinant murine IL-12 was kindly provided by Genetics Institute,
Cambridge, MA, USA. Recombinant human IL-10 was kindly provided
by Amgen, Thousand Oaks, CA, USA.
In vivo cytokine treatment by osmotic pump implantation
Two days before time of bead challenge mice were subjected to
ketamine anesthesia, the abdomen was prepped and cleaned with 70%
alcohol. A 0.8 cm incision was made in the skin and peritoneum through
which was implanted an osmotic pump (Alza Corp, Palo Alto, CA,
USA) containing 100ml of IL-10 or IL-12 solution with concentration
adjusted to achieve a constant infusion of 50mg/kg/day (about 40 ng/
mouse/h); this resulted in steady state serum cytokine concentrations of
3:2 6 0:9 ng/ml. Control pumps contained vehicle, PBS. After two days
rest, the mice were challenged I.V. with antigen-coated beads. Four
days after challenge, lungs and lymph nodes were excised and cultures
prepared as described below. In all experiments, samples of lungs were
fixed in 10% buffered formalin for morphometric analysis.
Granuloma, granuloma macrophage and lymph node culture
Groups of mice were killed 4 days after bead embolization, the expected
time of maximum lesion size. Following perfusion with cold RPMI,
lungs excluding trachea and major bronchi were excised, placed in cold
RPMI medium then homogenized in a Waring blender with a narrow-
bottom stainless steel cup. Intact GR were collected over a sterile
stainless steel mesh (#100) and rinsed with cold RPMI. Granuloma
macrophages were obtained by digestion of GR in a membrane
sterilized solution of RPMI-1640 medium (JRH Biosciences, Lenexa,
KS) containing 10% fetal bovine serum (Intergen, Purchase, NY),
10 mM glutamine, and 100 mg/ml streptomycin and 100 U/ml penicillin
(RPMI-FBS) containing 1000 U/ml type IV collagenase (Sigma, St.
Louis, MO, USA). Following 30 min incubation in a 378 shaker water
bath at 120 cycles/min, the digest was passed through a stainless steel
mesh (#100) and washed four times in RPMI-FBS. Macrophages were
isolated by 2 h adherence and monolayers were washed twice then
immediately cultured in the presence or absence of 1mg/ml endotoxin in
a 378C incubator with a 5% CO2, humidified atmosphere. Endotoxin
stimulation was best for evaluation of macrophage IL-12 and TNF
producing capacity. Supernatants were collected at 48 h and stored at
¹458C. Adherent cells on dishes were stained and the total number of
adherent macrophages were counted in order to normalize cytokine
production. Adherent cells were>90% macrophages based upon
morphology and nonspecific esterase staining. For differential counting,
duplicate cytospin preparations of digested granulomas were prepared
and stained with Wright’s stain.
Mediastinal lymph notes were collected at the time of lung harvest
and teased into single cell suspension. After washing, the cells were
cultured in RPMI FBS at 5× 106/ml in the presence or absence of 5mg/
ml PPD or SEA, then cultured as above for 36 h. Supernatants were
collected by centrifugation and stored at¹458C.
Cytokine measurement
Interleukins 2, 4, 5, 10, TNF and MCP-1 were measured by ELISA
using commercially available reagents (Pharmingen, San Diego, CA,
USA); sensitivities were at least 50 pg/ml. Commercially available
recombinant murine cytokines served as standards in all assays
(Genzyme, Cambridge, MA and Preprotech Inc., Rocky Hill, NJ,
USA). IL-12 was measured by sandwich ELISA as described [15] and
was sensitive to 50 pg/ml. Interferon-g was measured by ELISA as
described [16] using a capture antibody derived from the XMG-6 clone,
kindly provided by Dr. F. Finkelman, NIH; sensitivity was to 50 pg/ml.
Statistics
The Student’s t-test was used to compare groups. Values of p> 0:05
were considered to indicate lack of significance.
Results
Effect of IL-10 and IL-12 treatment on granuloma size
and composition
We initially examined the gross effect of IL-10 and IL-12
infusion on the overall size of PPD (type 1) and SEA (type 2)
pulmonary granulomas (GR). Figure 1 shows that IL-10
infusion (50mg/kg/d) did not alter the size of either type of
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Fig. 1. Effect of constant IL-10 or IL-12 infusion on the size of PPD
(type 1)- and SEA (type 2) pulmonary granulomas. CBA mice were
presensitized, implanted with control or cytokine infusion pumps then
challenged with PPD- or SEA-beads as described in Materials and
Methods. On day 4 of granuloma formation, lungs were excised, fixed,
and paraffin-embedded for histologic examination. Cross-sectional
areas of individual granulomas were determined by computerized
morphometric analysis. Bars are mean granuloma areasþ SEM of a
representative experiment (4–5 mice per group in each experiment). A
minimum of three separate experiments were performed.
lesion. It should be noted that an effect was likewise not
observed at doses of 100mg/kg/d (data not shown). In
contrast, IL-12 infusion caused a pronounced reduction in
the size of type 2 lesions (range 50–70% among three
separate experiments) but only a minimal reduction in type 1
lesions (range 5–16% among three separate experiments). It
should also be mentioned that no significant inflammatory
reaction was observed within the peritoneum in response to
the pumps or the infused cytokines.
In order to determine possible effects of GR composition,
differential analysis was performed on dispersed GR cells.
As shown in Table 1, type 1, PPD-bead lesions were com-
posed primarily of lymphocytes, mononuclear phagocytes,
and neutrophils, whereas type 2, SEA-bead lesions have a
significant component of eosinophils. Interleukin 10 treat-
ment reduced the neutrophil component of the type 1 lesion
while the type 2 lesion was unaffected. In contrast, IL-12
treatment did not significantly affect the type 1 lesion but it
virtually eliminated the eosinophil component of type 2
lesions, resulting in a composition similar to the type 1 lesion.
Effect of IL-10 and IL-12 treatment on granuloma
macrophage cytokine producing capacity
We previously reported that macrophages isolated from PPD
and SEA bead GR display different patterns of cytokine
production. Reflecting the differential participation of Th1
and Th2 cells [13, 14]. As shown in Figure 2A, GR macro-
phages of type 1 lesions display strong IL-12 and TNF but
weak MCP-1 production, whereas those of type 2 lesions
show weak IL-12 and TNF but strong MCP-1 production.
Levels of IL-10 were comparable in macrophage cultures of
both types of lesions.
Infusion of IL-10 had no effect on type 2 GR macro-
phages but caused a reduction of all cytokines produced by
type 1 GR macrophages (Fig. 2B). Infusions of IL-12
likewise had different effects on macrophages from the two
types of lesions (Fig. 2C). Interestingly, IL-12 had the
common effect of reducing MCP-1 production by macro-
phages of both lesion types but otherwise the effects differed.
While TNF and IL-10 were unaffected, extrinsic IL-12
seemed to impair intrinsic IL-12 producing capacity in the
type 1 lesion. In contrast, extrinsic IL-12 augmented
intrinsic IL-12 producing capacity as well as IL-10 and
TNF production by type 2 lesion macrophages. These
diverse effects on GR macrophages were likely the result
of influences on both macrophage function and T cell-
derived cytokine production.
Effect of IL-10 and IL-12 treatment on serum IFN-g levels
IL-10 and IL-12 are known to respectively suppress and
augment IFN-g production in vitro. In order to assess this
potential activity in vivo, levels of IFN-g were measured
in the sera of cytokine treated mice. As shown in Table 2,
IFN-g was detectable in the sera of PPD-bead challenged
mice but was undetected in the SEA-bead challenged mice.
Unexpectedly, IL-10 treatment did not decrease but rather
tended to increase levels of IFN-g in the type 1 response. As
would be predicted, IL-12 profoundly augmented serum
IFN-g levels in both PPD and SEA bead challenged mice.
Effect of IL-12 and IL-10 treatment on lymph node
cytokine profiles
In order to determine the regional effect of cytokine infusion
on lymphoid cell maturation, mediastinal lymph nodes cells
were collected from granuloma bearing mice and assessed
for antigen-induced cytokine profiles. As shown in Figure 3
(hatched bars), the type 1 PPD response was dominated by
IFN-g and IL-12 production. Treatment with IL-10 reduced
IL-12 in a manner consistent with our previously published
observations (Fig. 3A) [15]. Surprisingly, IL-10 augmented
IFN-g levels (Fig. 3A), an effect seemingly inconsistent with
its known ability to inhibit IFN-g synthesis. This paradoxical
result was consistent with the unexpected serum elevation of
IFN-g and indicated that there were cellular sources if IFN-g
resistant to the effects of IL-10.
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Table 1. Effect of IL-10 and IL-12 infusion
on cellular composition of PPD (type 1) and
SEA (type 2)-bead lesions.
Lesion type and treatment Lymphocytes Large mononuclears Eosinophils Neutrophils
PPD-bead (type 1)
PBS 566 4 346 5 16 1 96 3
IL-10 596 5 386 4 06 0 26 2*
IL-12 506 6 436 8 26 1 56 2
SEA-bead (type 2)
PBS 386 6 326 6 286 7 26 1
IL-10 406 6 336 2 256 6 26 1
IL-12 576 8* 39 6 9 16 1* 3 6 2
Values are mean percentages6 SD derived from three separate experiments. Differentials were
determined from Wright cytospin preparations of cells from enzymatically dispersed granulomas.
*p < 0:05.
Table 2. Serumg-interferon levels following IL-10 and IL-12 infusion
in PPD- and SEA-bead challenged mice.
Lesion type Treatment and IFN-g levels (ng/ml)
PBS IL-10 IL-12
PPD-bead (type 1) 0: 56 0:06 0:136 0:06 8:5 6 2:8*
SEA-bead (type 2) < 0:05 < 0:05 8:2 6 1:4*
Values are means6 SD. Serum was collected at the time of sacrifice,
day 4, and assayed for IFN-g by ELISA. Levels in untreated, naive mice
were less than lower limit of assay. *p< 0:005.
As expected, IL-12 treatment profoundly augmented
IFN-g and reduced IL-2 producing cells (Fig. 3B), likely
reflecting a shift from IL-2 producing precursors to mature
Th1 cells [17]. Since IL-2 levels were variable between
experiments, the latter effect was most evident in those
experiments with a larger pool of IL-2 producing cells.
Surprisingly, similar to our findings with IL-10, exogenous
IL-12 suppressed intrinsic IL-12 production, suggesting a
feedback regulatory loop.
The type 2 SEA response was dominated by IL-4, IL-5
and IL-10 production with weak IFN-g and negligible IL-12
production (Fig. 4). Unexpectedly, IL-10 reduced expression
of all Th2 cytokines as well as IFN-g (Fig. 4A). In contrast,
IL-2 levels were increased, suggesting a shift to less differ-
entiated T cells. As in the type 1 response, IL-12 infusion
augmented IFN-g and reduced IL-2 producing cells
(Fig. 4B). In addition, all Th2-related cytokines were
profoundly abrogated. These changes were consistent with
abolition of Th2 expression and conversion to a Th1-like
response.
Discussion
There is substantial evidence indicating that IL-10 and IL-12
are potent immunoregulatory cytokines and consequently
they are suspected to have potential therapeutic use.
Specifically, IL-10 is thought to have anti-inflammatory
properties by virtue of its ability to suppress the expression
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Fig. 2. Effect of constant IL-10 or IL-12 infusion on the production of
IL-10, IL-12, MCP-1 and TNF by isolated PPD (type 1)- and SEA (type
2)-bead granuloma macrophages. (A) Cytokine profiles of GR macro-
phages from mice with control PBS pumps. Patterns are not signifi-
cantly different from untreated mice. (B) Mice with IL-10 pumps. (C)
Mice with IL-12 pumps. Bars are means6 SEM and show levels of
spontaneously released IL-10 and MCP-1 and endotoxin-elicited IL-12
with TNF. Arrows indicate the direction of statistically significant
changes from mice with PBS pumps derived from three separate
experiments. All levels are normalized to 1× 06 macrophages.
Fig. 3. Effect of constant IL-10 or IL-12 infusion on cytokine profiles
of draining lymph node cell cultures from mice with PPD (type 1)
pulmonary granulomas. Mediastinal lymph nodes of control or cytokine
treated mice (4–5 mice/group) with 4 day, type 1 PPD GR were pooled,
dispersed and cultured in the presence or absence of PPD (5mg/ml) for
36 h. Supernatants were then assayed for the cytokines indicated. (A)
IL-10 treatment study; (B) IL-12 treatment study. Bars are means6
SEM of three determinations from a representative experiment. Three
separate experiments were performed. Left scale applies to IL-2, IL-4
and IL-12 and right scale to IL-5, IL-10, and IFN-g. Arrows indicate
direction of significant changes.
of a number of cytokines such as IFN-g, TNF and IL-1
[3–5]. Conversely, IL-12 has the ability to enhance IFN-g
and is thought to be proinflammatory [2, 7]. A variety of
animal models of human disease have been employed to
examine the effects of manipulating IL-10 and IL-12 in vivo.
For example, IL-10 treatment caused suppression of inflam-
mation in a model of viral keratitis [18] yet depletion of
IL-10 abrogated inflammation in a model of murine lupus
erythematosus [19]. Treatment with IL-12 promoted resist-
ance toMycobacteria[20], Cryptococcus[21], Leishmania
[22] andCryptosporidia[23], but impaired responses to the
intestinal parasite,Nippostrongylus brasiliensis[24]. While
these studies appear sometimes conflicting, they likely
reflect effects on different host immune mechanisms that
involve either Th1- or Th2-related cytokines. In addition,
unexpected findings may arise if cytokine manipulation
disrupts or invokes unknown regulatory circuits. In order to
help clarify the potential effects of IL-10 and IL-12
immunotherapy, the present study employed standardized
models of pulmonary granulomatous inflammation that are
mediated by predominantly Th1- (type 1) or Th2- (type 2)-
related cytokines [13, 14]. Unlike previous studies we used
constant IL-10 or IL-12 infusion and performed simultan-
eous comparisons of local cellular recruitment, GR macro-
phage function and regional lymphoid tissue responses. Our
results not only support a number of previously published
observations but provide novel information regarding the
local and regional effects of exogenous cytokine treatment
during Th1 or Th2 dominated immune responses. The
following discussion will summarize these findings and their
implications.
Infusion of IL-10 had no effect on the gross size of either
type 1 or type 2 GRs as determined by morphometry. This
finding is consistent with that of Powrie et al. who found that
IL-10 alone had no effect on the T cell-mediated inflam-
matory response toLeishmania major [8]. That study
showed that inhibition of T cell-mediated leukocytic
infiltration required combined IL-10 and IL-4 treatment.
Despite having no effect on lesion size, our study clearly
demonstrated that IL-10 had differing effects on GR cell
composition and macrophage function. Neutrophil content
was abrogated in type 1 GR which may be related to the
broad reduction in macrophage cytokine producing capacity
with associated reduction in leukocyte recruitment factors.
Similarly, IL-10 may have direct inhibitory effects on
neutrophils as reported by Wang et al. [25]. In contrast,
type 2 GR macrophages were resistant to extrinsic IL-10 and
GR cell composition was unaffected. This may be related to
the likelihood that cells of type 2 lesions are already exposed
to intrinsic IL-10 in the Th2-dominant immune environment.
For example, we recently reported that intrinsic IL-10 is in
part responsible for the impaired IL-12 producing capacity of
type 2 GR macrophages [15]. Similarly, Villaneuva et al.
showed that schistosome egg GR macrophages were subject
to intrinsic IL-10-mediated down-regulation of B-7 costi-
mulatory molecules [26].
In the draining lymphoid tissue, IL-10 infusion caused a
paradoxical augmentation of IFN-g production seemingly
inconsistent with its known Th1 inhibitory effects in vitro
[3–5]. Only speculative explanations can be offered at this
time. Perhaps, infused IL-10 may promote tachyphylaxis,
possibly via receptor desensitization, causing resistance to
IL-10 mediated suppression. Alternatively, IL-10 may
inhibit production of other factors that impair IFN-g pro-
ducing cells. Interestingly, the type 1 GR macrophages were
still subject to deactivation by exogenous IL-10, indicating a
differential sensitivity or adaptability of local and regional
responses. The finding that IL-10 caused macrophage
deactivation despite the presence of IFN-g is fully consistent
with studies of Fiorentino et al. [4].
Surprisingly, IL-10 inhibited the production of Th2-
related cytokines during the type 2 response seemingly
inconsistent with the in vitro studies of Fiorentino et al. [3].
Unlike type 2 GR macrophages, draining lymphoid cells
were not resistant to IL-10 treatment. The inhibitory effect
of IL-10 on Th2 cytokine profiles may be at the level of
antigen-presenting cells. In vitro studies of Kawamura and
Furue showed that IL-10 selectively downregulates the
expression of B7-2 [27], a costimulatory membrane antigen
thought to promote Th2 cell differentiation [17, 28]. Based
on this observation, IL-10 might be predicted to impair Th2
cell maturation as our results indicate. Alternatively, as noted
above, exogenous IL-10 may induce a tachyphylactic
response. We have previously shown that the Th2 profile
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Fig. 4. Effect of constant IL-10 or IL-12 infusion on cytokine profiles
of draining lymph node cell cultures from mice with SEA (type 2)
pulmonary granulomas. Mediastinal lymph nodes of control or cytokine
treated mice (4–5 mice/group) with 4 day, type 2 SEA GR were pooled,
dispersed and cultured in the presence or absence of SEA (5mg/ml) for
36 h. Supernates were then assayed for the cytokines indicated. (A) IL-
10 treatment study; (B) IL-12 treatment study. Bars are means6 SEM
of three determinations from a representative experiment. Left scale
applies to IL-2, IL-4 and IL-12 and right scale to IL-5, IL-10, and
IFN-g. Arrows indicate direction of significant changes.
in lymphoid tissues of SEA-bead challenged mice is in part
dependent on endogenous IL-10 [14]. Constant IL-10
infusion may induce resistance, indirectly eliminating the
Th2 supportive function of IL-10. Regardless of the under-
lying mechanism, this finding is of particular importance
since it suggests that while IL-10 treatment may not block
Th2 effector function, it may block Th2 cell maturation and
expansion within lymphoid tissues, thereby degrading
subsequent responses. Consequently, IL-10 may be useful
for treatment of Th2 based inflammatory diseases.
In addition to corroborating previously reported obser-
vations, our studies employing IL-12 infusions provide a
number of novel observations. As would be predicted, IL-12
promoted the expression of IFN-g producing cells in the
regional lymphoid tissue during both types 1 and 2 GR
formation. Furthermore, in accord with studies of Wynn et
al. [11] and Oswald et al. [12], IL-12 treatment profoundly
abrogated the eosinophil-rich GR response to schistosomal
egg antigens as well as Th2 cell expression in regional
lymphoid tissue. Despite the common effect of promoting
IFN-g production, our studies revealed subtle differences in
responses to IL-12 that suggest the presence of a complex
network of cytokine regulation as discussed below.
Extrinsic IL-12 suppressed intrinsic IL-12 producing
capacity in the type 1 response but augmented it in the type 2
response. We have previously shown that IL-12 is down-
regulated during the type 2 GR response by IL-4/IL-10
mediated suppression [15]. Presumably, extrinsic IL-12
largely eradicates the Th2 influence thereby relieving this
suppressive effect. In contrast, the type 1 GR response is
characterized by augmented IL-12 producing capacity.
Apparently, in this environment extrinsic IL-12 acts to
inhibit intrinsic IL-12 production, overcoming the known
stimulatory effect of IFN-g [29]. Thus, IL-12 can potentially
act in a feedback manner to limit its own production.
Differential regulatory effects of IL-12 were also
apparent with regard to GR macrophage IL-10 and TNF
production. The GR macrophages of type 1 lesions showed
no significant changes, whereas those of type 2 GR showed
augmentations of these cytokines. As with IL-12, the
enhanced TNF producing capacity may be due to lessened
IL-4/IL-10-mediated suppression [30] and augmented
IFN-g-mediated stimulation [31, 32]. The enhanced IL-10
expression is especially intriguing. In previous studies IL-12
injections enhanced IL-10 mRNA levels in lungs with
schistosome egg GR [11] and in livers of otherwise untreated
mice [33]. It is not clear if this is a direct or indirect effect. In
any case, these findings suggest another regulatory loop in
which IL-12 induces IL-10, a potential cross-regulatory
molecule. The apparent resistance of type 1 GR macro-
phages to this inducing effect is likewise intriguing and
further studies will be needed to determine the underlying
mechanism.
The abrogation of GR macrophage derived monocyte
chemotactic protein-1 (MCP-1) production by IL-12 infusion
was another novel finding. Inhibition was observed in both
types of lesions. At present, it is not clear if this is a direct or
indirect effect of IL-12. In addition to being produced at
higher levels by type 2 GR macrophages, depletion studies
indicate that MCP-1 contributes more to type 2 than to type 1
inflammation [34, 35]. Furthermore, we have recently
demonstrated that intrinsic MCP-1 supports Th2 cell
expression and directly inhibits IL-12 production [36].
Taken together, these data suggest that MCP-1 and IL-12
are cross-regulatory, extending the known functional roles of
these molecules.
The results of the present study emphasize the need to
understand the complexity of cytokine regulatory networks
as related to site (i.e. local, regional and systemic) and
immune status. Such knowledge will be essential to the
design of rational cytokine-based immunotherapy.
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